Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. (Q41931401)

14 October 2017

title

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. (English)

1 reference

14 October 2017

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Daniel Wright

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Katie J. Ewer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

11

Adrian V S Hill

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

9

Alison Lawrie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

3

Carly Bliss

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Nicholas A Anagnostou

2

object named as

Nicholas Anagnostou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1

Navin Venkatraman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

8

Ian Poulton

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Karin Lövgren-Bengtsson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Rachel Roberts

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

20 September 2017

1 reference

14 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

6208-6217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

The complexity of protective immunity against liver-stage malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Malaria vaccines and human immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Matrix-M adjuvant: enhancing immune responses by 'setting the stage' for the antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.09.028

10.1016/J.VACCINE.2017.09.028

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28941620%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference